Technical Analysis for AEMD - Aethlon Medical, Inc.

Grade Last Price % Change Price Change
F 0.39 -1.15% 0.00
AEMD closed down 1.15 percent on Thursday, November 21, 2024, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -1.15%
Bollinger Band Squeeze Range Contraction -1.15%
NR7 Range Contraction -1.15%

   Recent Intraday Alerts

Alert Time
20 DMA Resistance about 4 hours ago
Up 1% about 4 hours ago
Possible NR7 about 4 hours ago
Fell Below Previous Day's Low about 7 hours ago
Down 2 % about 7 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aethlon Medical, Inc. Description

Aethlon Medical, Inc., a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company's Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It is also developing exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.


Classification

Sector: Technology
Industry: Scientific & Technical Instruments
Keywords: Medicine Cancer Biology Infectious Diseases Treatment Of Cancer Neurological Disorders Coronavirus Hepatitis Viruses Immunodeficiency Urological Disorders Virus Antiviral Drug Exosome Sepsis Therapeutic Device Vesicles

Is AEMD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.3499
52 Week Low 0.2375
Average Volume 690,933
200-Day Moving Average 0.81
50-Day Moving Average 0.40
20-Day Moving Average 0.39
10-Day Moving Average 0.40
Average True Range 0.03
RSI (14) 45.65
ADX 18.75
+DI 19.44
-DI 15.72
Chandelier Exit (Long, 3 ATRs) 0.37
Chandelier Exit (Short, 3 ATRs) 0.46
Upper Bollinger Bands 0.42
Lower Bollinger Band 0.37
Percent B (%b) 0.31
BandWidth 11.22
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram -0.001
Fundamentals Value
Market Cap 960.77 Thousand
Num Shares 2.49 Million
EPS -4.77
Price-to-Earnings (P/E) Ratio -0.08
Price-to-Sales 7.55
Price-to-Book 0.42
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.41
Resistance 3 (R3) 0.41 0.40 0.40
Resistance 2 (R2) 0.40 0.40 0.40 0.40
Resistance 1 (R1) 0.39 0.39 0.40 0.39 0.40
Pivot Point 0.39 0.39 0.39 0.39 0.39
Support 1 (S1) 0.38 0.38 0.38 0.38 0.37
Support 2 (S2) 0.37 0.38 0.37 0.37
Support 3 (S3) 0.36 0.37 0.37
Support 4 (S4) 0.36